Genetic analyses in UK Biobank identifies 78 novel loci associated with urinary biomarkers providing new insights into the biology of kidney function and chronic disease

Daniela Zanetti^{1,2}, Abhiram Rao³, Stefan Gustafsson⁴, Themistocles Assimes¹, Stephen B. Montgomery^{5,6}, Erik Ingelsson^{1,2,4}

1. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA;
2. Stanford Cardiovascular Institute, Stanford University, Stanford, CA;
3. Department of Bioengineering, Stanford University, Stanford, CA;
4. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden;
5. Department of Pathology, Stanford University School of Medicine, Stanford, CA;
6. Department of Genetics, Stanford University School of Medicine, Stanford, CA.

Address for Correspondence:

Erik Ingelsson, MD, PhD, FAHA

300 Pasteur Dr, mail code: 5773; Stanford, CA 94305; USA

Phone: +1-650-656-0089; E-mail: eriking@stanford.edu

Running Title: Urinary biomarkers in UK Biobank

Word count: 4,816 (main text); 281 (abstract)

Abstract

Background:

Urine biomarkers, such as creatinine, microalbumin, potassium and sodium are strongly associated with several common diseases including chronic kidney disease, cardiovascular disease and diabetes mellitus. Knowledge about the genetic determinants of the levels of these biomarker may shed light on pathophysiological mechanisms underlying the development of these diseases.

Methods:

We performed genome-wide association studies of urinary levels of creatinine, microalbumin, potassium, and sodium in up to 326,441 unrelated individuals of European ancestry from the UK Biobank, a large population-based cohort study of over 500,000 individuals recruited across the United Kingdom in 2006-2010. Further, we explored genetic correlations, tissue-specific gene expression and possible causal genes related to these biomarkers.

Results:

We identified 23 genome-wide significant independent loci associated with creatinine, 20 for microalbumin, 12 for potassium, and 38 for sodium. We confirmed several established associations including between the *CUBN* locus and microalbumin (rs141640975, $p=3.11e-68$). Variants associated with the levels of urinary creatinine, potassium, and sodium mapped to loci previously associated with obesity (*GIPR*, rs1800437, $p=9.81e-10$), caffeine metabolism (*CYP1A1*, rs2472297, $p=1.61e-8$) and triglycerides (*GCKR*, rs1260326, $p=4.37e-16$), respectively. We detected high pairwise genetic correlation between the levels of four urinary biomarkers, and significant genetic correlation between their levels and several anthropometric, cardiovascular, glycemic, lipid and kidney traits. We highlight *GATM* as causally implicated in the genetic control of urine creatinine, and *GIPR*, a potential diabetes drug target, as a plausible causal gene involved in regulation of urine creatinine and sodium.

Conclusion:

We report 78 novel genome-wide significant associations with urinary levels of creatinine, microalbumin, potassium and sodium in the UK Biobank, confirming several previously established associations and providing new insights into the genetic basis of these traits and their connection to chronic diseases.

Author Summary

Urine biomarkers, such as creatinine, microalbumin, potassium and sodium are strongly associated with several common diseases including chronic kidney disease, cardiovascular disease and diabetes mellitus. Knowledge about the genetic determinants of the levels of these biomarker may shed light on pathophysiological mechanisms underlying the development of these diseases. Here, we performed genome-wide association studies of urinary levels of creatinine, microalbumin, potassium and sodium in up to 326,441 unrelated individuals of European ancestry from the UK Biobank. Further, we explored genetic correlations, tissue-specific gene expression and possible causal genes related to these biomarkers. We identified 78 novel genome-wide significant associations with urinary biomarkers, confirming several previously established associations and providing new insights into the genetic basis of these traits and their connection to chronic diseases. Further, we highlight *GATM* as causally implicated in the genetic control of urine creatinine, and *GIPR*, a potential diabetes drug target, as a plausible causal gene involved in regulation of urine creatinine and sodium. The knowledge arising from our work may improve the predictive utility of the respective biomarker and point to new therapeutic strategies to prevent common diseases.

Introduction

Fluctuating levels of several urinary biomarkers are used clinically to assess an individual's renal function as well as to diagnose and predict the onset of related chronic diseases(1). These biomarkers include creatinine, microalbumin, potassium, sodium, and other proteins and peptides which have been associated with chronic kidney disease (CKD) (2, 3) cardiovascular disease (CVD) (4-8), and type 2 diabetes (T2D) (9, 10). Urinary biomarkers have also shown promise in monitoring response to therapy (11). In comparison to blood, biomarkers in urine are less subject to homeostatic mechanisms. This situation allows for greater fluctuations of biomarker levels which in turn may provide a signal that more reliably reflects dynamic changes in human biological and pathophysiological processes (12).

Little progress has been made in disentangling the genetic determinants of levels of urinary biomarkers in large population cohorts despite extensive research on the genetic determinants of biomarkers in blood (13-16), including estimated glomerular filtration rate (17). Discovering such associations and identifying whether they are genetically correlated with other common traits and physiological metrics may provide important etiological insights into their control. This knowledge may in turn improve the predictive utility of the respective biomarker and point to new therapeutic strategies to prevent common diseases.

In this context, we performed a genome-wide association study (GWAS) of four urine biomarkers individually - creatinine, microalbumin, potassium and sodium - in up to 326,441 participants of the UK Biobank (UKB) study. For each urinary biomarker, we estimated its heritability, identified genetic associations that were likely mediated by expression or methylation quantitative trait loci (eQTLs or mQTLs), evaluated genetic correlations with several anthropometric, cardiovascular, glycemic, lipid, hematological and kidney traits, and used a bioinformatics approach to pinpoint tissues that were significantly enriched for associated variants, as well as candidate causal genes.

Results

Association analyses

We found a total of 93 genome-wide significant independent variants associated with any of the four urine biomarkers: 23 for creatinine (N = 327,857), 20 for microalbumin (N = 326,441), 12 for potassium (N = 327,147), and 38 for sodium (N = 327,162) (Table 1, Figures 1a-d). A total of 85 lead variants are novel, while 8 are located in loci previously associated with kidney function, including *CUBN* (35), *CPS1*, *GATM* and *SHROOM3* (36). Out of the 85 novel variant associations, three were shared across creatinine, potassium and sodium (rs2472297, rs4410790 and rs784257) and one between creatinine and potassium (rs13143189); consequently, we report a total of 78 novel and unique loci associated with urinary biomarkers.

Many of the 78 novel lead SNPs associated with any of the four urine biomarkers are located near loci (± 250 kb) previously reported to be associated with several complex diseases/traits as compiled by the GWAS catalog (S2 Table). For our creatinine loci, the strongest associations (based on the lowest p-values in p-value) were found for height (37), lung cancer (38), schizophrenia (39), human blood cells (40), coffee consumption (41), basal cell carcinoma (42), breast cancer (43), BMI (44), kidney function (17), Crohn's disease (45), intraocular pressure (46), circulating parathyroid hormone (47), and liver enzyme in plasma (48). Only one locus (rs13143189) had no associations with GWAS catalog traits. For our 14 microalbumin loci, the strongest associations were found with male-pattern baldness (49), educational attainment (50), human blood cells (40), allergic disease (51), and prostate cancer (52). Furthermore, 5 variants are located near *CUBN*, a well-known locus for albuminuria (35) (Table 1) and 6 loci have no previously known associations with traits in the GWAS catalog. For potassium, the strongest associations were found with breast cancer (53), esophageal adenocarcinoma (54), schizophrenia (39), human blood cells (40), neuroticism (55), and resting heart rate (56) (S2 Table). For sodium, the strongest associations were found with human blood cells (40), BMI (57), lipid levels (58), fasting plasma glucose (59), educational attainment (50), intelligence (60), neuroticism (55), alcohol consumption (61), retinal vascular caliber (62), liver enzyme in plasma (48), triglycerides (63), schizophrenia (39), breast cancer (53), blood pressure (64), non-glioblastoma glioma (65), lung cancer (38), and mumps (66). A total of 7 loci had no previously known association with a GWAS catalog trait.

Regional plots for the 92 discovered loci are shown in S1-S4 Figs. We observed minor inflation in test statistics ($\lambda=1.149$ for creatinine, 1.033 for microalbumin, 1.107 for potassium, and 1.158 for sodium), which is expected (67) under polygenic inheritance in large samples (S5a-d Fig). The gene-level association identified 51, 11, 31 and 42 genes associated at GWAS significance with creatinine, microalbumin, potassium and sodium, respectively (S6 Fig, S3 Table). Several of these genes have been previously associated with complex traits, such as *CPS1*, *GATM/SPATA5L1* and *GIPR* (creatinine) which have been implicated in the development of atherosclerosis (68), CKD (17) (36) and obesity (44), respectively. We confirmed the association with *CUBN* (microalbumin), a well-known locus for albuminuria (35). The potassium locus including *ELL* showed association with several cancers including prostate (18), lung (69) and esophagus (70), while the *FTO* locus for sodium coincides with the first and strongest locus identified to date for BMI through GWAS (44).

Table 1. Genetic loci associated with urine biomarkers in the genome-wide association studies.

creatinine										
CHR	pos	SNP	Function	Nearest gene (bp distance)	EA	OA	EAF	beta	SE	P_VALUE
1	41490761	rs61780440	intergenic	SLFN1 (1,852)	C	G	0.191	0.018	0.003	9.23E-10
1	77967507	rs71658797	intronic	AK5	A	T	0.123	0.023	0.004	3.80E-11
1	98253738	rs10747486	intronic	DPYD	G	A	0.776	-0.015	0.003	2.54E-08
1	171451621	rs35041900	downstream	snoU13 **	T	C	0.093	0.022	0.004	3.56E-08
2	211540507	rs1047891	exonic	CPS1	A	C	0.316	0.020	0.002	2.58E-16
4	3757380	rs13143189	intergenic	AC141928.1 * (3,095)	A	G	0.436	-0.015	0.002	8.65E-11
6	31804729	rs11968400	5 prime UTR	C6orf48	T	C	0.055	0.029	0.005	1.07E-08
6	32075563	rs429150	intronic	TNXB	C	T	0.442	0.013	0.002	2.62E-08
6	32587165	rs9271377	intergenic	HLA-DQA1 (8,791)	G	T	0.366	-0.014	0.002	1.44E-08
7	17284577	rs4410790	intergenic	AC003075.4 (34,881)	C	T	0.634	-0.021	0.002	1.63E-18
7	75611756	rs3815455	intronic	POR	T	C	0.290	-0.015	0.003	1.38E-09
8	77372988	rs56099375	ncRNA_intronic	LINC01111	T	C	0.243	-0.016	0.003	5.28E-09
10	22058137	rs10740991	intronic	DNAJC1	C	G	0.719	-0.017	0.003	1.47E-10
14	29635571	rs7142377	intergenic	RP11-562L8.1 (98,460)	A	G	0.812	0.018	0.003	1.35E-09
15	45661678	rs1288775	exonic	GATM	A	T	0.256	0.016	0.003	8.17E-10
15	75027880	rs2472297	intergenic	CYP1A1 (9,929)	T	C	0.267	-0.027	0.003	7.97E-26
16	20355811	rs34262842	intronic	UMOD	G	A	0.167	-0.018	0.003	8.49E-09
16	50914706	rs4488444	ncRNA_intronic	CTD-2034I21.2	G	A	0.756	0.015	0.003	1.18E-08
18	53397199	rs784257	ncRNA_intronic	RP11-397A16.1 *	C	T	0.813	0.026	0.003	8.00E-18
19	41392490	rs79600176	intronic	CTC-490E21.12	C	T	0.022	0.048	0.008	1.14E-09
19	46181392	rs1800437	exonic	GIPR	C	G	0.193	-0.018	0.003	9.81E-10
22	23412017	rs3788337	intronic	RTDR1	A	G	0.353	-0.014	0.002	3.37E-09
22	24897743	rs762279	intronic	UPB1	A	G	0.581	-0.013	0.002	2.62E-08
microalbumin										
CHR	POS	SNP	Function	Nearest gene (bp distance)	EA	OA	EAF	BETA	SE	P_VALUE
1	47961691	rs10157710	intergenic	RPL21P24 (1,875)	T	C	0.801	0.099	0.016	3.10E-10
2	226684886	rs183131780	intergenic	LOC646736 (322,654)	T	C	0.002	0.888	0.099	2.39E-19
2	227459951	rs71431010	intergenic	MIR5702 (63,475)	A	G	0.001	2.215	0.139	6.62E-57
2	228511926	rs34823645	intronic	C2orf83	C	T	0.001	1.660	0.142	9.54E-32
3	170027407	rs112607182	intergenic	PRKCI (3,638)	T	C	0.075	0.162	0.023	6.03E-13
4	77413142	rs7675217	intronic	SHROOM3	C	G	0.538	-0.077	0.012	2.30E-10
4	149132756	rs6535594	intronic	NR3C2	A	G	0.495	0.069	0.012	1.36E-08

4	190769223	rs4109437	ncRNA_intronic	AF146191.4 *	A	G	0.038	0.265	0.029	1.51E-20
6	15138733	rs12527322	intergenic	JARID2 (107,994)	T	A	0.213	-0.089	0.015	4.33E-09
7	29805361	rs17158386	intergenic	WIPF3 (40,741)	A	G	0.261	0.083	0.014	1.42E-09
10	16874217	rs565411930	intron	CUBN	T	C	0.000	1.680	0.215	5.95E-15
10	16932384	rs45551835	missense	CUBN	A	G	0.014	0.634	0.039	7.49E-59
10	16938271	rs77744173	intronic	CUBN	G	T	0.099	0.213	0.019	2.08E-29
10	16992011	rs141640975	missense	CUBN	A	G	0.003	1.254	0.072	3.11E-68
10	17005743	rs539606836	intronic	CUBN	A	G	0.000	2.055	0.210	1.52E-22
10	77885337	rs7909516	intronic	C10orf11	T	C	0.224	0.085	0.014	2.56E-09
11	9959698	rs147971756	intronic	SBF2	T	C	0.049	-0.169	0.031	2.98E-08
11	78937277	rs74976749	intronic	TENM4	A	G	0.000	1.820	0.303	1.89E-09
15	41903965	rs8036643	intronic	TYRO3	C	G	0.645	0.075	0.013	6.05E-09
17	56086784	rs147347791	upstream	SRSF1	G	A	0.008	0.340	0.061	2.11E-08
potassium										
CHR	POS	SNP	Function	Nearest gene (bp distance)	EA	OA	EAF	BETA	SE	P VALUE
3	27413566	rs4973766	downstream	SLC4A7	T	C	0.456	-0.016	0.002	2.20E-10
4	3757380	rs13143189	intergenic	AC141928.1 * (3,095)	A	G	0.436	-0.020	0.002	2.53E-16
5	560476	rs17563576	intergenic	MIR4456 (24,479)	G	A	0.195	-0.021	0.003	2.39E-11
6	28712247	rs1233578	intergenic	RPSAP2 (11,566)	G	A	0.179	-0.024	0.003	4.13E-14
6	31308988	rs1634776	intronic	HLA-B	T	C	0.152	-0.019	0.003	3.97E-08
6	32005267	rs431204	upstream	CYP21A2	T	C	0.126	-0.024	0.004	3.66E-10
7	17284577	rs4410790	intergenic	AC003075.4 (34,881)	C	T	0.634	-0.015	0.003	4.05E-09
11	126735193	rs7947480	intronic	KIRREL3	T	A	0.783	-0.016	0.003	3.95E-08
12	48693423	rs2634697	intergenic	RP11-37010.2 * (15,430)	C	T	0.257	-0.016	0.003	2.46E-08
12	64747352	rs12303483	ncRNA_intronic	RPS11P6	A	T	0.083	0.024	0.004	4.85E-08
15	75027880	rs2472297	intergenic	CYP1A1 (9,929)	T	C	0.267	-0.016	0.003	1.61E-08
18	53397199	rs784257	ncRNA_intronic	RP11-397A16.1 *	C	T	0.813	0.019	0.003	1.60E-09
sodium										
CHR	POS	SNP	Function	Nearest gene (bp distance)	EA	OA	EAF	BETA	SE	P VALUE
1	54734191	rs3766428	intronic	SSBP3	C	G	0.452	-0.013	0.002	2.13E-08
1	72714331	rs1194277	intronic	NEGR1	G	C	0.508	0.015	0.002	7.21E-10
2	27730940	rs1260326	missense	GCKR	C	T	0.607	-0.020	0.002	4.37E-16
2	45155276	rs13383034	ncRNA_intronic	RP11-89K21.1 *	T	C	0.308	0.015	0.003	5.74E-09
2	51930164	rs1516187	ncRNA_intronic	AC007682.1	C	T	0.867	0.021	0.004	4.28E-09
2	100986964	rs1437971	exonic	AC012493.2	C	A	0.650	-0.017	0.003	4.72E-11
3	35699022	rs11706708	intronic	ARPP21	T	C	0.213	0.019	0.003	6.31E-11
4	100239319	rs1229984	missense	ADH1B	C	T	0.978	-0.044	0.008	3.31E-08
5	87682877	rs7442885	ncRNA_intronic	TMEM161B-AS1	G	C	0.210	-0.019	0.003	2.17E-10
5	148099993	rs13188076	intergenic	ADRB2 (106,163)	T	G	0.232	-0.016	0.003	2.14E-08
6	31241182	rs6900444	intronic	HLA-C	T	C	0.469	0.013	0.002	2.12E-08
6	32029415	rs204886	synonymous	TNXB	C	T	0.504	0.013	0.002	4.67E-08
6	51258579	rs2504706	intergenic	RP3-437C15.2 (7,932)	C	T	0.235	-0.022	0.003	1.15E-15
6	54070858	rs2754809	intronic	C6orf142	G	C	0.297	0.015	0.003	3.05E-08
6	98333409	rs12189679	ncRNA_exonic	RP11-436D23.1	A	G	0.465	-0.016	0.002	4.00E-11
7	17284577	rs4410790	intergenic	AC003075.4 (34,881)	C	T	0.634	-0.017	0.002	6.91E-12
7	73035857	rs7800944	intronic	MLXIPL	C	T	0.287	-0.017	0.003	3.25E-10
7	132064270	rs62466423	intronic	PLXNA4	T	C	0.085	-0.023	0.004	4.32E-08
7	132727695	rs55861011	intronic	CHCHD3	T	C	0.314	-0.014	0.003	3.17E-08
8	143495760	rs140154612	intergenic	RP13-467H17.1 (7,371)	C	T	0.018	-0.056	0.010	4.75E-09
9	139107925	rs11103388	intronic	QSOX2	A	G	0.330	0.015	0.003	3.47E-09
9	140296734	rs778597957	intronic	EXD3	A	G	0.000	0.651	0.117	2.68E-08
10	22208630	rs2807978	intronic	DNAJC1	C	T	0.712	-0.017	0.003	8.31E-11
10	63466754	rs2393831	intronic	C10orf107	G	A	0.223	-0.016	0.003	2.51E-08
10	65191645	rs7924036	intronic	JMJD1C	T	G	0.503	-0.013	0.002	3.89E-08
11	28845569	rs2945091	ncRNA_intronic	RP11-115J23.1 *	A	G	0.558	-0.015	0.002	1.10E-09
11	31300793	rs2210143	intronic	DCDC1	G	T	0.322	-0.017	0.003	2.77E-11
11	118584498	rs569770	ncRNA_intronic	AP002954.4	C	T	0.641	0.014	0.002	4.22E-08
12	78773251	rs12581220	ncRNA_intronic	RP11-754N21.1	T	C	0.316	-0.018	0.003	3.50E-12
14	29781178	rs1957111	ncRNA_intronic	RP11-562L8.1	T	C	0.052	0.034	0.005	3.90E-10
15	75027880	rs2472297	intergenic	CYP1A1 (9,929)	T	C	0.267	-0.020	0.003	2.54E-14
16	53802494	rs11642015	intronic	FTO	T	C	0.402	0.018	0.002	4.01E-14
17	3492998	rs12936340	intronic	TRPV1	A	G	0.643	0.014	0.002	3.93E-08
18	1839601	rs8097672	intergenic	RP11-161I6.2 * (43,924)	T	A	0.145	0.019	0.003	1.94E-08
18	53397199	rs784257	ncRNA_intronic	RP11-397A16.1 *	C	T	0.813	0.017	0.003	4.20E-08
19	41350615	rs28399462	synonymous	CYP2A6	A	G	0.023	0.052	0.008	7.26E-11
19	46180414	rs34783010	intronic	GIPR	T	G	0.193	-0.022	0.003	1.24E-13
19	49259529	rs838133	synonymous	FGF21	G	A	0.550	0.021	0.002	7.91E-17

Abbreviations: CHR, chromosome; pos, position; SNP, single-nucleotide polymorphism; GWAS, genome-wide association study; EA, effect allele; OA, other allele; EAF, effect allele frequency; SE, standard error.

** SnoRNA; *LincRNA.

LD score regression

We found evidence of high genetic correlation between every pair of the 4 urinary biomarkers, although the correlations between microalbumin and the other three biomarkers were generally lower (0.20-0.28), than between the other three (0.53-0.81). Further, we observed significant genetic correlation between the urinary biomarkers and several anthropometric, cardiovascular, glycemic, lipid, hematologic and kidney traits (Figure 2, S4 Table). Specifically, we identified a significant and positive genetic correlation across creatinine, microalbumin and sodium and several traits related to cardiometabolic disease including BMI, body fat, obesity, WHR, fasting insulin, and triglycerides. In addition, we detected significant negative correlation between urinary creatinine and eGFR_{crea}; and between three urinary biomarkers (creatinine, microalbumin and sodium) and HDL. We observed a significant and positive correlation between potassium and obesity, and a strong inverse correlation between potassium and systolic blood pressure. The heritability of the four urine biomarkers was in the range of $0.015 \leq h^2_g \leq 0.069$ (Table 2).

Table 2. Genome-wide heritability of the four urine biomarkers.

	h2g_obs	h2g_obs_se	h2g_int	h2g_int_se
Creatinine	0.065	0.003	1.022	0.010
Microalbumin	0.015	0.002	1.008	0.007
Potassium	0.042	0.002	1.019	0.009
Sodium	0.069	0.003	1.033	0.010

Abbreviations: h2g, genome-wide heritability; obs, observed; se, standard error; int, intercept.

Functional analysis

Most of the significant SNP associations we identified were located in intronic or intergenic regions, rather than in exons or regulatory regions (S7-8 Figs). Most genome-wide significant SNPs across the four urine biomarkers were predicted to have no or weak effects on transcription based on the prevalent minimum (most active) chromatin state (S9 Fig). DEPICT

analyses identified hematologic and immune systems as the most enriched physiological systems for loci associated with creatinine; cardiovascular systems for microalbumin; and nervous systems for potassium and sodium biomarkers. However, none of the DEPICT analyses reached statistical significance ($FDR < 0.05$, S10 Fig, S5 Table). Genes identified by gene-level associations as associated with creatinine were enriched among upregulated DEG sets in the liver, and genes associated with microalbumin were enriched among downregulated gene sets in the bladder (Bonferroni corrected P -value ≤ 0.05). The other biomarkers did not show any significant relationship across the genes expressed in the 53 tissue types of GTEx (S11-12 Fig).

Colocalization with eQTL and mQTL summary statistics

We detected four significant eQTL probe colocalizations for creatinine (S6 Table). No significant eQTL colocalization signals were detected for microalbumin, potassium and sodium. We observed 43 significant mQTL probe colocalizations for creatinine, two for microalbumin, 157 for potassium and 30 for sodium; however, many probes were found to map to the same region and are likely representing the same methylation effect (S7 Table). We observed a total of 24 independent (r^2 for top SNPs > 0.5) and high confidence colocalizations at loci with significant eQTL and/or mQTL SMR p -values (Table 3).

- *Creatinine*

We detected significant eQTL colocalizations for *GATM* (lead SNP rs2467858, SMR $p = 9.51e-9$) and *SPATA5L1* (lead SNP rs9788780, SMR $p = 1.67e-9$) on chromosome 15 (Figure 3, Table 3); these GWAS signals colocalized with several mQTL probes in the region as well (S7 Table). The most strongly associated GWAS variant was rs1288775 ($\beta = 0.016$, p -value $= 8.17e-10$) (Table 1), and all colocalization lead variants at this locus were strongly linked ($LD\ r^2 > 0.9$). We identified an eQTL colocalization on chromosome 15 at the *COMMD4* locus (lead SNP rs9673084, $p = 7.01e-6$). We also observed two additional clusters of mQTL colocalizations on chromosome 15, one set with lead variants including eQTLs (or linked variants) for *CYP1A1/CYP1A2* (top probe SNP rs2472297, $p = 3.49e-9$), and another set with lead variants including eQTLs for *SCAMP2* (top probe lead SNP rs4886649, $p = 2.49e-9$). However, we did not observe eQTL colocalizations for both these genes in blood. We also observed an eQTL colocalization at the *POR* locus on chromosome 7 (lead SNP rs11983987,

$p=1.72e-7$). Although there were no mQTL colocalizations with lead SNPs in strong linkage with rs11983987, we detected 4 colocalizations of mQTL probes with lead SNPs in weak linkage ($LD\ r^2 \sim 0.4$). The SNPs rs13143189 ($p = 8.56e-11$), rs9271377 ($p = 1.44e-8$), rs2472297 ($p = 7.97e-26$) and rs1800437 ($p = 9.81e-10$) showed significant association in the GWAS analysis and significant colocalization with methylation probes. These SNPs are close to *ADRA2C* on chromosome 4, *HLA-DQA1* on chromosome 6, *CYP1A2* on chromosome 15 and *GIPR* on chromosome 19, respectively (Table 3).

- *Microalbumin*

We detected significant mQTL colocalizations for *ADM* on chromosome 11 (lead SNP rs4910113, SMR $p = 9.52e-7$) and consistent signals in GWAS and mQTL colocalization analyses for *SHROOM3* on chromosome 4 (rs7675258, $p = 6.99e-7$).

- *Potassium*

We detected consistent signals in GWAS and mQTL colocalization analyses for the *CYP1A1* locus on chromosome 15 (rs2472297, $p = 9.38e-6$). Most mQTL probe colocalizations ($n = 134$) for potassium occurred for probes binding within a 5.5 Mb region on chromosome 6 (chr6:27277996-32729059), which overlaps with the HLA region. These colocalizations clustered into three broad groups based on linkage of their lead variants; identification of genes is complicated by the linkage structure of this region of the genome (S7 Table).

- *Sodium*

We detected consistent significant mQTL signals for the *TBL2* locus on chromosome 7 (rs12540011, $p = 1.27e-8$), for the *CYP1A1* locus on chromosome 15 (rs2472297, $p = 1.88e-7$), and for the *GIPR* (rs10423928, $p = 4.34e-12$) and *FGF21* loci (rs838133, $p = 8.32e-12$) on chromosome 19.

We also detected shared mQTL colocalizations between urine biomarkers. Creatinine and potassium shared an mQTL colocalization (with multiple probes) on chromosome 4; the lead SNP rs12641452 of the top probe is located within a *POLR2A* binding site in a 25kb region flanking *ADRA2C*. Creatinine and sodium shared an mQTL colocalization near *GIPR* on chromosome 19 with the same lead variant rs10423928 identified across multiple probes. The methylation probes that colocalize with the GWAS signal at this locus bind in or near a high confidence *CTCF* binding site in an intronic region of *GIPR*.

Table 3. Consistent significant signals across genome-wide association studies, expression quantitative trait loci (eQTL) and/or methylation quantitative trait loci (mQTL) probe colocalizations.

eQTL														
	ProbeChr	topSNP_bp	topSNP	Nearest gene	A1	A2	Freq	b_GWAS	se_GWAS	p_GWAS	b_eQTL	se_eQTL	p_eQTL	p_SMR
creatinine	7	75657850	rs11983987	POR	G	A	0.182	-0.017	0.003	2.85E-08	0.4	0.026	1.41E-54	1.72E-07
	15	45711492	rs2467858	GATM	G	A	0.276	0.016	0.003	1.31E-09	-0.383	0.022	2.44E-70	9.51E-09
	15	45685487	rs9788780	SPATA5L1	A	T	0.273	0.016	0.003	1.19E-09	0.85	0.019	8.63E-103	1.67E-09
	15	75622943	rs9673084	COMMD4	A	G	0.245	-0.016	0.003	2.92E-10	0.139	0.022	1.48E-10	7.01E-06
mQTL														
creatinine	1	41487317	41560291	SCMH1	A	G	0.197	0.016	0.003	6.20E-09	0.629	0.037	3.40E-64	3.88E-08
	1	78442554	78623626	GIPC2,LOC100132264	T	C	0.1	0.021	0.003	6.44E-10	0.527	0.046	4.99E-30	5.61E-08
	4	3748154	3748134	LOC100129786,ADRA2C	A	C	0.404	0.015	0.002	9.28E-10	-0.636	0.032	2.61E-88	4.87E-09
	6	32165183	32587165	HLA-DRB1,HLA-DQA1	G	T	0.383	-0.014	0.002	1.44E-08	-0.322	0.034	2.45E-21	1.14E-06
	7	17337976	17338147	LOC100131512	T	C	0.136	0.019	0.003	1.46E-08	0.419	0.047	3.84E-19	1.70E-06
	7	75624427	75695081	MDH2	A	G	0.173	-0.017	0.003	1.74E-08	-0.69	0.042	1.72E-61	9.55E-08
	15	74891207	75027880	CYP1A1,CYP1A2	T	C	0.231	-0.027	0.003	7.97E-26	0.264	0.037	9.21E-13	3.49E-09
	15	75165896	75328595	SCAMP2	C	T	0.335	-0.016	0.002	1.61E-10	-0.531	0.032	4.05E-61	2.49E-09
	19	46181546	46182304	GIPR	A	T	0.208	-0.018	0.003	1.52E-09	-0.804	0.039	2.13E-93	6.81E-09
microalbumin	4	77409957	77413179	SHROOM3	G	A	0.489	0.077	0.012	2.83E-10	0.268	0.033	0	6.99E-07
	11	10323902	10269178	ADM	G	A	0.22	0.079	0.015	2.36E-07	-0.63	0.041	0	9.52E-07
potassium	4	3748154	3748134	LOC100129786,ADRA2C	A	C	0.404	0.018	0.003	3.95E-12	-0.636	0.032	2.61E-88	5.64E-11
	5	601475	599269		A	G	0.198	-0.018	0.003	2.23E-09	-0.991	0.035	4.23E-177	4.87E-09
	6	28830902	28934352		C	T	0.073	-0.025	0.004	2.44E-11	-1.597	0.039	8.63E-120	4.35E-11
	15	74891207	75027880	CYP1A1,CYP1A2	T	C	0.231	-0.016	0.003	1.61E-08	0.264	0.037	9.21E-13	9.38E-06
sodium	7	72993570	72991704	TBL2	A	G	0.269	-0.015	0.003	3.94E-09	0.755	0.034	1.68E-109	1.27E-08
	8	143484414	143527647		T	C	0.016	-0.043	0.008	2.65E-08	-1.178	0.11	5.79E-27	7.77E-07
	15	74891207	75027880	CYP1A1,CYP1A2	T	C	0.231	-0.02	0.003	2.54E-14	0.264	0.037	9.21E-13	1.88E-07
	19	46181546	46182304	GIPR	A	T	0.208	-0.022	0.003	1.87E-13	-0.804	0.039	2.13E-93	4.34E-12
	19	49259452	49259529	FGF21	A	G	0.418	-0.021	0.002	7.91E-17	0.386	0.032	7.59E-33	8.32E-12

Abbreviations: CHR chromosome; pos, position; SNP, single-nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effect allele frequency; b, beta; p, p-value; SMR, summary-based-results Mendelian Randomization.

Discussion

Principal findings

We achieved three broad goals in this study of up to 326,441 unrelated UKB participants of European descent. We (1) established the genetic determinants of levels of creatinine, microalbumin, potassium and sodium in urine, (2) evaluated genetic correlation between these biomarkers and several physiological measurements, and (3) explored the functional impact of associated loci using variant annotations, tissue-specific gene expression patterns, and colocalization analysis with expression and methylation summary statistics. Our main findings are several-fold. First, we report a total of 78 novel loci associated with one or more of the 4 urine biomarkers, providing new leads regarding biological processes involved in regulating urinary creatinine, microalbumin, potassium and sodium. Second, our analyses indicate low heritability, but high pairwise genetic correlation for the four urinary biomarkers; as well as significant genetic correlations with several traits related to chronic kidney disease, cardiovascular disease, and type 2 diabetes. Third, we highlight a significant positive relationship for creatinine and microalbumin and genes highly expressed in liver and bladder, respectively. Fourth, we identify 4 and 20 independent colocalization events of GWAS data with blood gene expression and DNA methylation respectively, and we provide evidence for a functional mechanism at colocalized GWAS loci. As an example of the latter, we identified *GATM* and *SPATA5L1* as possible causal genes involved in the genetic underpinning of urinary creatinine; and *GIPR*, a potential drug target in the treatment of obesity-associated metabolic disorders, as a plausible causal gene involved in regulation of urine creatinine and sodium.

Comparison with prior literature

This study is the first GWAS of urinary creatinine, potassium and sodium to the best of our knowledge while genetic determinants of microalbumin have already been explored in previous, smaller studies (10, 35). In this study, we replicated the well-known association in *CUBN*, and extend prior GWAS of microalbumin by highlighting several novel pathways influencing this trait. We also replicated the known association of variants in the *CPS1* locus with serum creatinine, previously reported to affect creatinine production and secretion; and

with *GATM*, a gene that encodes a mitochondrial enzyme previously associated with serum creatinine (36).

Previous epidemiological studies have showed significant associations between sodium and potassium intake and CVD (6, 7), and between higher levels of sodium and lower levels of potassium intake and higher blood pressure (8), but there is a lack of studies studying the genetics underpinning of these biomarkers. Our genetic correlation analysis confirmed a negative association of blood pressure with urinary potassium, and the positive association with urinary sodium. We also confirmed a significant positive genetic correlation between creatinine, microalbumin and sodium and several anthropometric measurements related with CVD (BMI, body fat, obesity and WHR), and with fasting insulin, and triglycerides. In addition, we detected significant negative correlations of urinary creatinine, microalbumin and sodium with HDL.

We report heritability estimates of the 4 urinary biomarkers in the range of 2-7%, which is lower than many complex traits, but quite consistent with prior studies of kidney-related biomarkers. Previous studies applying family-based designs have generally reported similar, but somewhat higher estimates for other kidney-related biomarkers (71-73). Specifically, the estimates for albumin/creatinine ratio, potassium and sodium have been reported to be in the range of 13-19 %, lowest for potassium and highest for creatinine (71, 73). This discrepancy can probably be explained by prior studies focusing on serum biomarkers, and due to differences in statistical methods used. Indeed, our method captures SNP-based heritability due to common variation, whereas twin and other family-based analyses also capture components of heritability due to rare variation (74).

Novel biology

We observed colocalization of the GWAS signal for urine creatinine at *GATM* and *SPATA5L1* with both eQTL and mQTL signals in the region. The *GATM* locus is not novel in terms of association with renal function as previous studies have shown its association with CKD and reduced glomerular filtration rate (17, 36). *GATM*, which stands for glycine amidinotransferase, encodes a rate-limiting enzyme involved in creatinine biosynthesis, and has been suggested to act as a functional link between statin-mediated lowering of cholesterol and susceptibility to statin-induced myopathy (75). In addition, a previous study showed a significant association

of SNPs in the *GATM* locus with plasma and urine creatinine but not with cystatin C in plasma, another biomarker of renal function (36). This association may indicate that the regulatory variant(s) in this locus influence creatinine production rather than creatinine excretion. Consistent with this finding, our genetic correlation analysis indicated a significant negative association of urine and eGFR_{crea} ($p = 2.08 \times 10^{-6}$), but no significant correlation with eGFR_{cys}, pointing more broadly to common pathways between urine and serum creatinine. The colocalization lead variants for all eQTL and mQTL probes in the region were strongly linked with each other and with the previously reported statin-induced response eQTL rs9806699 for *GATM* ($LD\ r^2 > 0.9$). Consistent with the expectation that increased methylation of CpG-dense promoters correlates negatively with gene expression, the linked lead eQTL and mQTL colocalization SNPs showed association with decreased *GATM* expression and increased methylation in the region (S6 Table).

Variants in *SHROOM3* showed significant association with microalbumin in the GWAS and in the mQTL colocalization. *SHROOM3* encodes an actin-associated protein important in epithelial morphogenesis that has been previously shown to be strongly associated with kidney function (36). Studies in zebrafish and rat show that alterations in *SHROOM3* can result in glomerular dysfunction. Furthermore, human *SHROOM3* variants can induce impaired kidney function in animal models (76). Variants near *CYP1A1* on chromosome 15 showed a significant association with urinary creatinine, potassium and sodium in the GWAS; and in the mQTL colocalization analysis. This locus has been previously suggested as a potential drug target for the prevention of CVD because variants in this locus are also associated with blood pressure (77). Likewise, variants in the *GIPR* locus significantly associated with creatinine and sodium in our GWAS and mQTL colocalization have been previously associated with several cardiometabolic traits including obesity (78), BMI (44), and hip circumference (79). The glucose-dependent insulintropic peptide (GIP) has a central role in glucose homeostasis through its amplification of insulin secretion. Incretin hormones such as GIP act to promote efficient uptake and storage of energy after food ingestion and have become important players for glucose homeostasis in pancreatic and extra pancreatic tissue. A recent study demonstrated that mice with selective ablation of GIPR in beta cells exhibited lower levels of meal-stimulated insulin secretion, decreased expansion of adipose tissue mass and preservation of insulin sensitivity when compared to controls (80). Hence, the GIPR represents

a potential therapeutic in the treatment of diabetes. Similarly, the fibroblast growth factor 21 (*FGF21*) significant associated with sodium in our GWAS and mQTL colocalization, is considered a novel promising candidate in the treatment of T2D, obesity, dyslipidemia, cardiovascular and fatty liver diseases (81). *FGF21* encodes a fibroblast growth factor involved in glucose and lipid metabolism, and has been previously associated with macronutrient intake (82). In vitro, *FGF21* promotes insulin-dependent glucose uptake through the transcription of GLUT1 in rodent and human adipocytes (83). Pharmacologic doses of *FGF21* improve glucose clearance and insulin sensitivity, and lower plasma triglycerides and free fatty acids in diabetic and obese animal models (84, 85). In humans, the role of *FGF21* remains ill-defined, but reports have linked serum levels of *FGF21* with adiposity, fasting insulin, and triglycerides (86).

Strengths and limitations

Strengths of the present study include the very large sample size with both genetic profiling and phenotypic data which enabled us to detect a large number of genetic associations, the use of state-of-the-art methods to validate our results including a conservative analytical framework with strict multiple testing correction, and a variety of pathway analyses. Furthermore, our study is the most comprehensive to date on the genetics of urine biomarkers, combining GWAS, genetic correlation, as well as functional and eQTL and mQTL colocalization analyses.

We also acknowledge some limitations. First, we did not replicate our findings in an external study sample due to unavailability of a similar independent large study; although we applied an internal replication strategy given the very large sample size. Second, participants included in our analyses were restricted to middle-aged and elderly individuals of European ancestry potentially limiting the generalizability of our results to other age groups and ethnicities.

Conclusions

We report 78 novel genome-wide significant associations with urinary creatinine, microalbumin, potassium and sodium in the UKB, confirming several known associations and providing new insights into the genetic basis of these traits and their connection to chronic diseases. We detected high genetic correlations between the four urinary biomarkers and

significant genetic correlations with several anthropometric, cardiovascular, glycemic, lipid and kidney traits. Through this effort, we highlight *GATM* as a plausible causal gene controlling levels of urinary creatinine, and *GIPR* – a potential diabetes drug target – as being associated with urine creatinine and sodium.

Materials and Methods

Study sample

The UKB is a longitudinal cohort study of over 500,000 individuals aged 40-69 years at the time of recruitment between 2006 and 2010. Participants were enrolled in 22 study centers located in England, Scotland and Wales. The UKB study was approved by the North West Multi-Centre Research Ethics Committee and all participants provided written informed consent. Details of these measurements can be found in the study protocol (18) and in the UKB Data Showcase (<http://biobank.ctsu.ox.ac.uk/crystal/>).

Phenotype

Urine samples were collected at baseline in all UKB participants. All urinary biomarker measurements were carried out on a single Beckman Coulter AU5400 clinical chemistry analyzer using the manufacturer's reagents and calibrators, except for urinary microalbumin, which used reagents and calibrators sourced from Randox Bioscience. Internal quality control was performed for all the four urinary biomarkers data (http://biobank.ctsu.ox.ac.uk/crystal/docs/urine_assay.pdf). Baseline characteristics of UKB participants who had included in the analyses are shown in S1 Table. Details of these measurements can be found in the UKB Data Showcase (<http://biobank.ctsu.ox.ac.uk/crystal/>). We used rank-based inverse normal transformed phenotype levels in all continuous association tests performed.

Genotypes

Genotyping was performed with the UK BiLEVE and UK Biobank Axiom arrays (Affymetrix Research Services Laboratory, Santa Clara, California, USA). Initial quality control (QC) was conducted centrally by the UKB, and has been described in detail by Bycroft et al (19). At the time of this study, genotype data was available for 488,377 participants at 805,426 markers;

genotype imputation was also conducted centrally using IMPUTE2 and a reference panel from the Haplotype Reference Consortium (HRC) (19). In our analysis, we used the July 2017 release of the imputed genetic marker data, and excluded genetic markers with minor allele count ≤ 30 and imputation quality < 0.8 . As a result, the total number of genetic markers included in our analysis was 15,640,977.

Genetic association analysis

We excluded individuals who had withdrawn consent at the time of this study, who were related, and who did not self-report as white or did not cluster with Europeans based on principal component analysis of genetic data (N=337,542). Unrelated individuals were defined as those who were no closer than the third-degree based on pairwise kinship coefficients by Bycroft et al (19).

In remaining participants, we performed GWAS to identify genetic variants associated with each of the 4 biomarkers (creatinine, N = 327,857 [3.0% missing values]; microalbumin, N = 326,441 [3.3% missing values]; potassium, N = 327,147 [3.1% missing values]; sodium, N = 327,162 [3.1% missing values]). Urine creatinine ($\mu\text{mol/L}$; ID 30510), potassium (mmol/L ; ID 30520) and sodium (mmol/L ; ID 30530) were analyzed as continuous traits, while microalbumin (mg/L ; ID 30500) was dichotomized into a binary trait ($\leq 30 \text{ mg/L} = 0$ and $>30 \text{ mg/L} = 1$)(20). The rationale for dichotomizing urinary microalbumin was that the distribution was bimodal, as expected in a community-based sample where the majority has no measurable urine albumin. We conducted association analyses with PLINK (version 2.0) (21) using linear or logistic regression of biomarker levels on imputed genotypes assuming an additive model between phenotypes and genotype dosages. We adjusted all models for age, sex, batch (3 levels; UK BiLEVE, UK Biobank release 1 and UK Biobank release 2) and the first ten genotype principal components, and restricted association analyses to single nucleotide polymorphisms (SNPs) with minor allele count ≥ 30 and imputation quality information score (info) ≥ 0.8 .

We pruned results based on distance retaining variants with the strongest associations within this distance for downstream analysis. We identified regions containing one or more SNPs with $p < 5e-8$ ("index SNPs") by screening a window of 500kb adjacent to the first index SNP on each chromosome. If no additional SNPs were identified, the region was limited to that

specific SNP, and screening was continued at the next index SNP. If additional index SNPs were present in this 500kb window, the window was expanded by a distance of 300kb from the last SNP in search of additional SNPs with $p < 5e-8$ until no more SNPs with $p < 5e-8$ within the next 300kb could be found. From this pruning, we identified a number of regions containing one to several index SNPs and assigned the SNP with lowest p-value within each region as the lead SNP. Within each region, we repeated association analysis after including all index SNPs in the region as well as lead SNPs from other regions on the same chromosome. We considered any SNP with a $p < 5e-8$ in this final analysis to be an independent locus. Regional plots were created for the association test results at significant loci using LocusZoom v1.4 (22).

LD-score regression

We applied LD-score regression (23) using available GWAS summary statistics from the LD Hub database (24) to evaluate genome-wide heritability (h^2_g) of the four urine biomarkers and to identify genetic correlation with other traits. We used pre-calculated European LD scores and restricted the analysis to SNPs found in HapMap Phase 3 (25). We evaluated pairwise genetic correlations of all four urine biomarkers, and between each biomarker and a total of 27 other traits. Specifically, we analyzed correlations with anthropometric (body mass index [BMI], body fat percentage, height, obesity, waist-hip ratio [WHR]), cardiovascular (atrial fibrillation, coronary artery disease, diastolic and systolic blood pressure, heart rate, ischemic stroke), glycemic (T2D, fasting glucose and insulin, 2-hour glucose adjusted for BMI, and glycated hemoglobin), lipid (high and low density lipoprotein cholesterol [HDL-C and LDL-C], triglycerides and total cholesterol), hematologic (mean platelet, platelet count) and kidney (CKD, estimated glomerular filtration rate of creatinine [eGFR_{crea}] and cystatin c [eGFR_{cys}]) traits. A conservative Bonferroni-corrected threshold of $4.46e-04$ (adjusting for 28 traits * 4 biomarkers) was used to identify significant correlations.

Functional analysis

We evaluated all genome-wide significant loci for functional impact using variant annotations, gene-level analysis, and colocalization analyses. We annotated chromatin states of all significant SNPs based on the 15-state model used in the NIH Roadmap Epigenomics study (26), and added functional annotations using RegulomeDB categories (27). We used predicted

gene functions as implemented in DEPICT (28) to provide biological interpretation of association signals and identify relevant tissues contributing to the signals. To balance power with specificity, DEPICT analysis was performed in two ways: 1) by including independent loci at genome-wide significance; 2) by including loci at a lower significance level ($p \leq 10^{-5}$) in the GWAS after pruning variants in high LD ($r^2 > 0.05$). Apart from a SNP-level GWAS, we conducted a MAGMA gene-level association analysis using gene-level tests as implemented in the FUMA GWAS platform (29). We explored pathways and tissues that were significantly enriched for associated genes using MAGMA (30). Tissue specificity was determined in 53 tissues based on gene expression data from the Genotype Tissue Expression project (GTEx V6) (31). We also determined whether the genes identified by gene-level associations were overrepresented in differentially expressed gene sets (DEG) for each tissue as implemented in FUMA. In these gene-based tests, two-sided Student's t-tests were performed per gene per tissue against all other tissues. After Bonferroni correction, genes with corrected P-value < 0.05 and absolute log fold change ≥ 0.58 were defined as a DEG set in a given tissue. We distinguished between genes that are upregulated and downregulated in a specific tissue compared to other tissues, by taking the sign of t-score into account. Genes were tested against those DEG sets by hypergeometric tests to evaluate if the prioritized genes are overrepresented in DEG sets in specific tissue types.

Colocalization with eQTL and mQTL summary statistics

We performed summary data-based Mendelian Randomization (SMR) (32) with blood cis-eQTL and cis-mQTL data to evaluate the evidence for colocalization between biomarker GWAS and white blood cell gene expression or methylation signals. We used colocalization to refer to evidence of a causal mechanism between expression and/or methylation and the GWAS signal. eQTL and mQTL colocalization analyses were performed at the level of individual probes; eQTL summary statistics were obtained from Westra et al. (33), and mQTL summary statistics were obtained from McRae et al. (34). We tested 5,959 and 93,220 probes which had genome wide significant cis-eQTLs and cis-mQTLs, respectively (QTL p-value $< 5 \times 10^{-8}$), and controlled false discoveries using Benjamini-Yekutieli (5% FDR) control in both analyses. As some genes have multiple gene expression probes, we estimated pairwise LD between all significant eQTL colocalization lead SNPs while analyzing results to ensure that

the same colocalization was not reported using multiple probes. Similarly, multiple methylation probes map to a given region; hence, we repeated the above process while reporting mQTL colocalizations as well.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 13721. This research was performed with support from National Institutes of Health (1R01HL135313-01).

Conflicts of Interest

Dr. Ingelsson is a scientific advisor for Precision Wellness and Olink Proteomics for work unrelated to the present project.

References

1. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. *Mol Cell Proteomics*. 2006;5(10):1760-71.
2. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. *J Am Soc Nephrol*. 2008;19(7):1283-90.
3. Tesch GH. Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. *Nephrology (Carlton)*. 2010;15(6):609-16.
4. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*. 2006;355(25):2631-9.
5. Ingelsson E, Sundstrom J, Lind L, Riserus U, Larsson A, Basu S, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. *European heart journal*. 2007;28(14):1739-45.
6. Cook NR, Obarzanek E, Cutler JA, Buring JE, Rexrode KM, Kumanyika SK, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. *Arch Intern Med*. 2009;169(1):32-40.
7. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. *Jama*. 2011;305(17):1777-85.
8. Jackson SL, Cogswell ME, Zhao L, Terry AL, Wang CY, Wright J, et al. Association Between Urinary Sodium and Potassium Excretion and Blood Pressure Among Adults in the United States: National Health and Nutrition Examination Survey, 2014. *Circulation*. 2018;137(3):237-46.
9. Ekinici EI, Cheong KY, Dobson M, Premaratne E, Finch S, Macisaac RJ, et al. High sodium and low potassium intake in patients with Type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2010;27(12):1401-8.
10. Teumer A, Tin A, Sorice R, Gorski M, Yeo NC, Chu AY, et al. Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. *Diabetes*. 2016;65(3):803-17.
11. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. *Clin Cancer Res*. 2008;14(8):2378-86.
12. Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. *Expert review of proteomics*. 2015;12(6):623-36.
13. Svensson-Farbom P, Almgren P, Hedblad B, Engstrom G, Persson M, Christensson A, et al. Cystatin C Is Not Causally Related to Coronary Artery Disease. *PloS one*. 2015;10(6):e0129269.
14. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. *Lancet (London, England)*. 1989;2(8677):1434-6.
15. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *Jama*. 2009;302(1):49-57.
16. Franceschini N, van Rooij FJ, Prins BP, Feitosa MF, Karakas M, Eckfeldt JH, et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. *American journal of human genetics*. 2012;91(4):744-53.

17. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nature communications*. 2016;7:10023.
18. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015;161(5):1215-28.
19. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. 2017. Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*. <https://doi.org/10.1101/166298>.
20. Toto RD. Microalbuminuria: definition, detection, and clinical significance. *Journal of clinical hypertension (Greenwich, Conn)*. 2004;6(11 Suppl 3):2-7.
21. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015;4:7.
22. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics (Oxford, England)*. 2010;26(18):2336-7.
23. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47(3):291-5.
24. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics (Oxford, England)*. 2017;33(2):272-9.
25. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. *Nature*. 2010;467(7311):52-8.
26. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nature biotechnology*. 2010;28(10):1045-8.
27. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome research*. 2012;22(9):1790-7.
28. Pers TH, Karjalainen JM, Chan Y, Westra HJ, Wood AR, Yang J, et al. Biological interpretation of genome-wide association studies using predicted gene functions. *Nature communications*. 2015;6:5890.
29. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nature communications*. 2017;8(1):1826.
30. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS computational biology*. 2015;11(4):e1004219.
31. The Genotype-Tissue Expression (GTEx) project. *Nature genetics*. 2013;45(6):580-5.
32. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet*. 2016;48(5):481-7.
33. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nature genetics*. 2013;45(10):1238-43.
34. McRea A, Marioni RE, Shah S, Yang J, Powell JE, Harris SH, et al. Identification of 55,000 Replicated DNA Methylation QTL. *bioRxiv*. <https://doi.org/10.1101/166710>.

35. Boger CA, Chen MH, Tin A, Olden M, Kottgen A, de Boer IH, et al. CUBN is a gene locus for albuminuria. *Journal of the American Society of Nephrology : JASN*. 2011;22(3):555-70.
36. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. *Nature genetics*. 2010;42(5):376-84.
37. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature*. 2010;467(7317):832-8.
38. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nature genetics*. 2017;49(7):1126-32.
39. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-7.
40. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell*. 2016;167(5):1415-29.e19.
41. Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. *Molecular psychiatry*. 2015;20(5):647-56.
42. Chahal HS, Wu W, Ransohoff KJ, Yang L, Hedlin H, Desai M, et al. Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. *Nature communications*. 2016;7:12510.
43. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature genetics*. 2013;45(4):353-61, 61e1-2.
44. Graff M, Scott RA, Justice AE, Young KL, Feitosa MF, Barata L, et al. Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults. *PLoS genetics*. 2017;13(4):e1006528.
45. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-24.
46. Choquet H, Thai KK, Yin J, Hoffmann TJ, Kvale MN, Banda Y, et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. *Nature communications*. 2017;8(1):2108.
47. Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, et al. Genetic Variants Associated with Circulating Parathyroid Hormone. *Journal of the American Society of Nephrology : JASN*. 2017;28(5):1553-65.
48. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nature genetics*. 2011;43(11):1131-8.
49. Pirastu N, Joshi PK, de Vries PS, Cornelis MC, McKeigue PM, Keum N, et al. GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. *Nature communications*. 2017;8(1):1584.
50. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. Genome-wide association study identifies 74 loci associated with educational attainment. *Nature*. 2016;533(7604):539-42.

51. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nature genetics*. 2017;49(12):1752-7.
52. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. *Nature genetics*. 2011;43(8):785-91.
53. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017;551(7678):92-4.
54. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. *The Lancet Oncology*. 2016;17(10):1363-73.
55. Luciano M, Hagenaars SP, Davies G, Hill WD, Clarke TK, Shiri M, et al. Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. *Nature genetics*. 2018;50(1):6-11.
56. Eppinga RN, Hagemeijer Y, Burgess S, Hinds DA, Stefansson K, Gudbjartsson DF, et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. *Nature genetics*. 2016;48(12):1557-63.
57. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nature genetics*. 2010;42(11):937-48.
58. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. *Nature genetics*. 2013;45(11):1274-83.
59. Hwang JY, Sim X, Wu Y, Liang J, Tabara Y, Hu C, et al. Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians. *Diabetes*. 2015;64(1):291-8.
60. Hill WD, Marioni RE, Maghzian O, Ritchie SJ, Hagenaars SP, McIntosh AM, et al. A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence. *Molecular psychiatry*. 2018.
61. Clarke TK, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, et al. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117). *Molecular psychiatry*. 2017;22(10):1376-84.
62. Ikram MK, Sim X, Jensen RA, Cotch MF, Hewitt AW, Ikram MA, et al. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. *PLoS genetics*. 2010;6(10):e1001184.
63. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010;466(7307):707-13.
64. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nature genetics*. 2011;43(10):1005-11.
65. Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. *Nature genetics*. 2017;49(5):789-94.

66. Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. *Nature communications*. 2017;8(1):599.
67. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. *Nature genetics*. 2014;46(11):1173-86.
68. Hartiala JA, Tang WH, Wang Z, Crow AL, Stewart AF, Roberts R, et al. Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. *Nature communications*. 2016;7:10558.
69. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. *Genome research*. 2012;22(11):2109-19.
70. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nature genetics*. 2013;45(5):478-86.
71. Moulin F, Ponte B, Pruijm M, Ackermann D, Guessous I, Ehret G, et al. 5C.09: Heritability of renal function parameters and electrolyte levels in the Swiss population. *Journal of hypertension*. 2015;33 Suppl 1:e70.
72. Arpegard J, Viktorin A, Chang Z, de Faire U, Magnusson PK, Svensson P. Comparison of heritability of Cystatin C- and creatinine-based estimates of kidney function and their relation to heritability of cardiovascular disease. *Journal of the American Heart Association*. 2015;4(1):e001467.
73. Fox CS, Yang Q, Guo CY, Cupples LA, Wilson PW, Levy D, et al. Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: the Framingham Heart Study. *Kidney international*. 2005;67(1):70-4.
74. Ge T, Nichols TE, Lee PH, Holmes AJ, Roffman JL, Buckner RL, et al. Massively expedited genome-wide heritability analysis (MEGHA). *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(8):2479-84.
75. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. *Nature*. 2013;502(7471):377-80.
76. Yeo NC, O'Meara CC, Bonomo JA, Veth KN, Tomar R, Flister MJ, et al. Shroom3 contributes to the maintenance of the glomerular filtration barrier integrity. *Genome research*. 2015;25(1):57-65.
77. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. *Nature genetics*. 2009;41(6):666-76.
78. McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, et al. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. *The American journal of clinical nutrition*. 2012;95(6):1477-86.
79. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;518(7538):187-96.
80. Campbell JE, Ussher JR, Mulvihill EE, Kolic J, Baggio LL, Cao X, et al. TCF1 links GIPR signaling to the control of beta cell function and survival. *Nature medicine*. 2016;22(1):84-90.

81. Zhao Y, Dunbar JD, Kharitonov A. FGF21 as a therapeutic reagent. *Advances in experimental medicine and biology*. 2012;728:214-28.
82. Tanaka T, Ngwa JS, van Rooij FJ, Zillikens MC, Wojczynski MK, Frazier-Wood AC, et al. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. *The American journal of clinical nutrition*. 2013;97(6):1395-402.
83. Kharitonov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. *The Journal of clinical investigation*. 2005;115(6):1627-35.
84. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. *Diabetes*. 2010;59(7):1817-24.
85. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. *Diabetes*. 2010;59(11):2781-9.
86. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. *Diabetes*. 2008;57(5):1246-53.

Figures

Figure 1. Manhattan plot for genetic associations for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d). The nearest gene for each chromosome labeled. Negative $\log_{10}$ -transformed P values for each SNP (y axis) are plotted by chromosomal position (x axis). The gray line represents the threshold for genome-wide statistically significant associations ($P = 5 \times 10^{-8}$). Red points represent significant hits.

c.

d.

Figure 2. Genetic correlations between urinary creatinine, microalbumin (a), potassium and sodium (b) and other traits. Significant correlations after Bonferroni correction (4.46×10^{-4}) are highlighted with a red triangle.

a.

b.

Abbreviations: BMI, body mass index; WHR, waist-hip ratio; AF, atrial fibrillation; CAD, coronary artery disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; HR, heart rate; IS, ischemic stroke; T2D, type 2 diabetes; FG, fasting glucose; FI, fasting insulin; 2hrGluAdjBMI, 2-hour glucose adjusted for BMI; HbA1C, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides; TC, total cholesterol; CKD, chronic kidney disease; eGFRcrea, estimated glomerular filtration rate of creatinine; eGFRcys, estimated glomerular filtration rate of cystatin.

Figure 3. Expression quantitative trait loci (eQTL) and methylation quantitative trait loci (mQTL) colocalization probes for the locus *GATM/SPATA5L1*. Colocalization of GWAS, eQTL and mQTL signals at the *GATM* locus on chromosome 15. eQTL signals for *GATM* and *SPATA5L1*, and the two top mQTL probes are shown, along with their respective colocalization top variants (determined by maximum SMR effect size).

Supporting Information

Tables

ST1 Table. Baseline characteristics of UK Biobank participants who had included in the analyses.

Abbreviations: SD, standard deviation; T2D, type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist-to-hip ratio.

S2 Table. GWAS catalog reference for genetic loci (500 bp) of the 78 novel lead variants associated with urine biomarkers in the genome-wide association studies. GWAS hits are highlighted and associations are sorted by p-value. GWAS catalog references were selected applying the following filters: minimum p values of 5e10-8, minimum samples size of 10000 for continuous traits and 5000 cases for binary traits.

Abbreviations: SNP, single-nucleotide polymorphism; POS, position; CHR, chromosome; PMID, pub med identification number.

S3 Table. P-value per gene-based genome-wide analysis for urinary biomarkers.

Abbreviations: CHR, chromosome; SNP, single-nucleotide polymorphism; P, p-value.

S4 Table. Genetic correlation between urinary biomarkers and other traits.

Abbreviations: rg, genetic correlation; P, p-value; BMI, body mass index; WHR, waist-hip ratio; AF, atrial fibrillation; CAD, coronary artery disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; HR, heart rate; IS, ischemic stroke; T2D, type 2 diabetes; FG, fasting glucose; FI, fasting insulin; 2hrGluAdjBMI, 2 hours glucose adjusted for BMI; HbA1C, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides; TC, total cholesterol; CKD, chronic kidney disease; eGFRcrea, estimated glomerular filtration rate of creatinine; eGFRcys, estimated glomerular filtration rate of cystatin c.

S5 Table. P-value of tissue enrichment for urinary biomarkers.

S6 Table. Significant expression quantitative trait loci (eQTL) probe colocalizations for creatinine.

Abbreviations: Chr, chromosome; bp, base position; SNP, single-nucleotide polymorphism; A1, effect allele; A2, other allele; Freq, minor allele frequency; b, beta; se, standard error; p, p-value; GWAS, genome-wide association study; eQTL, expression quantitative trait loci; SMR, summary-based-results Mendelian Randomisation; HEIDI, heterogeneity in dependent instruments.

S7 Table. Significant methylation quantitative trait loci (mQTL) probe colocalizations for creatinine, potassium and sodium.

Abbreviations: Chr, chromosome; bp, base position; SNP, single-nucleotide polymorphism; A1, effect allele; A2, other allele; Freq, minor allele frequency; b, beta; se, standard error; p, p-value; GWAS, genome-wide association

study; eQTL, expression quantitative trait loci; SMR, summary-based-results Mendelian Randomisation; HEIDI, heterogeneity in dependent instruments; p.BY, Benjamini Yekutieli adjusted p-value.

Figures

S1 Figure. Regional association and linkage disequilibrium plots for 23 genome-wide

significant loci for creatinine. The y axis represents the negative logarithm (base 10) of the SNP P value and the x axis represents the position on the chromosome, with the name and location of genes in the UCSC Genome Browser shown in the bottom panel. The SNP with the lowest P value in the region is marked by a purple diamond. The colors of the other SNPs indicate the r^2 of these SNPs with the lead SNP. Plots were generated with LocusZoom.

S2 Figure. Regional association and linkage disequilibrium plots for 20 genome-wide

significant loci for microalbumin. The y axis represents the negative logarithm (base 10) of the SNP P value and the x axis represents the position on the chromosome, with the name and location of genes in the UCSC Genome Browser shown in the bottom panel. The SNP with the lowest P value in the region is marked by a purple diamond. The colors of the other SNPs indicate the r^2 of these SNPs with the lead SNP. Plots were generated with LocusZoom.

S3 Figure. Regional association and linkage disequilibrium plots for 12 genome-wide

significant loci for potassium. The y axis represents the negative logarithm (base 10) of the SNP P value and the x axis represents the position on the chromosome, with the name and location of genes in the UCSC Genome Browser shown in the bottom panel. The SNP with the lowest P value in the region is marked by a purple diamond. The colors of the other SNPs indicate the r^2 of these SNPs with the lead SNP. Plots were generated with LocusZoom.

S4 Figure. Regional association and linkage disequilibrium plots for 38 genome-wide

significant loci for sodium. The y axis represents the negative logarithm (base 10) of the SNP P value and the x axis represents the position on the chromosome, with the name and location of genes in the UCSC Genome Browser shown in the bottom panel. The SNP with the lowest P value in the region is marked by a purple diamond. The colors of the other SNPs indicate the r^2 of these SNPs with the lead SNP. Plots were generated with LocusZoom.

S5 Figure. Q-Q plot for genetic associations for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d).

S6 Figure. Gene-based genome-wide analysis for urinary creatinine (a), microalbumin

(b), potassium (c) and sodium (d). The significant genes for each chromosome labeled. Negative log₁₀-transformed P values for each gene (y axis) are plotted by chromosomal position (x axis). The gray line represents the thresholds for genome-wide statistically significant associations ($p = 5e-08$).

S7 Figure. Functional categories for the genome-wide significant SNPs for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d).

S8 Figure. The Regulome database score for the genome-wide significant SNPs for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d).

S9 Figure. The minimum (most active) chromatin state for the genome-wide significant SNPs for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d).

S10 Figure. Tissue enrichment for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d).

S11 Figure. Differentially Expressed Gene (DEG) Sets across 30 general tissue types for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d). Significant enrichment at Bonferroni corrected P-value ≤ 0.05 are colored in red.

S12 Figure. Differentially Expressed Gene (DEG) Sets across 53 specific tissue types for urinary creatinine (a), microalbumin (b), potassium (c) and sodium (d). Significant enrichment at Bonferroni corrected P-value ≤ 0.05 are colored in red.